Supplementary Methods

Monitoring of CMV and EBV reactivation in the peripheral blood
Surveillance was started one week after transplantation and performed weekly for both viruses throughout the inpatient period ( Figure S1 ). Monitoring was sustained weekly for the first 100 days and then depending on requirements on 2-3 weekly basis. Peripheral blood donor chimerism was assessed between day 30-60 (Table S1) .
DNA used for quantitative real-time PCR was extracted from whole blood samples Quantification of real-time PCR was done on an ABI7500 instrument using the TaqMan Universal PCR Master Mix (Life Technologies). The lower limit of detection for CMV or EBV infection is at 250 virus copies per milliliter of peripheral blood.
Verification of virus IgG serology
Serology status for CMV and EBV was determined by the chemoluminescent microparticle CMIA assay (Abbott Diagnostics, Germany) on an Architect i2000 analyzer.
Cell sorting
PBMC were stained with the following antibodies for flow cytometric sorting: anti-CD4 FITC (SK3), anti-CD8 PE (SK1), anti-CD14 PerCP (MφP9, all clones BD Biosciences), and anti-TCRαβ (BW242/412, Miltenyi Biotec).
